- Conditions
- Cervical Dystonia Adults ,, Abnormal Head Position and Neck Pain for These 7 Muscle Groups: Splenius,Scalene,Sterno-cleido-mastoid,Levator Scapulae,Semispinalis,Trapezius,and Longissimus.
- Interventions
- Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, Efficacy of Botox intramuscularly at Week 30, Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, Efficacy of Botox subdermally at Week 30, Adverse Reactions of Botox intramuscularly, Adverse Reactions of Botox subdermally
- Drug
- Lead sponsor
- li nguyen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Westminster, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Choroid Plexus Neoplasm, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade II Meningioma, Adult Medulloblastoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Papillary Meningioma, Adult Pineal Gland Astrocytoma, Adult Pineoblastoma, Adult Primary Melanocytic Lesion of Meninges, Adult Supratentorial Primitive Neuroectodermal Tumor, Malignant Adult Intracranial Hemangiopericytoma, Metastatic Malignant Neoplasm in the Brain, Multiple Sclerosis, Recurrent Adult Brain Neoplasm
- Interventions
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadobutrol, Gadopentetate Dimeglumine
- Procedure · Drug · Radiation
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Diagnostic Self Evaluation, Central Nervous System Diseases
- Interventions
- Dotarem (gadoterate meglumine), Magnevist (gadopentetate dimeglumine)
- Drug
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Indian Wells, California + 14 more
- Conditions
- Fibrosis, Kidney Failure, Renal Insufficiency
- Interventions
- Gadopentetate dimeglumine (Magnevist, BAY86-4882)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Chula Vista, California • Los Angeles, California + 19 more
- Conditions
- Brain Pathology
- Interventions
- Multihance
- Drug
- Lead sponsor
- Bracco Diagnostics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- ISCHEMIC CARDIOMYOPATHY
- Interventions
- 'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Ischemic Heart Disease
- Interventions
- Regadenoson
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Central Nervous System Diseases
- Interventions
- gadobenate dimeglumine
- Drug
- Lead sponsor
- Bracco Diagnostics, Inc
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Congenital Heart Disease
- Interventions
- Gadopiclenol, Gadobenate dimeglumine
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Myocardial Infarction
- Interventions
- Magnevist (Gadopentetate dimeglumine, BAY86-4882)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 6
- States / cities
- San Diego, California • Winston-Salem, North Carolina • Tulsa, Oklahoma + 3 more
- Conditions
- Motor Function, Cognitive Function, Contrast Media
- Interventions
- Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Gadobenate dimeglumine, Gadodiamide, Gadoterate meglumine, Gadobutrol, Gadoteridol
- Procedure · Drug
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 2,076 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • New Haven, Connecticut • Chicago, Illinois + 11 more
- Conditions
- Suspicion of, or Known Breast Cancer
- Interventions
- Radiology/MRI scan
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Liver Tumor
- Interventions
- MRI with Multihance, MRI with Eovist
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Magnetic Resonance Imaging Contrast Agents
- Interventions
- Magnevist, Dotarem, Gadovist
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 500 participants
- Timeline
- 1990 – 2019
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Nashville, Tennessee
- Conditions
- Upper Limb Spasticity Unilaterally in Adults With History of Stroke, Increased Muscle Tone in Elbow, Wrist, Finger, and Thumb Flexors.
- Interventions
- Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12,, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, Efficacy of Botox intramuscularly at Week 30, Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, Efficacy of Botox subdermally at Week 30, Adverse Reactions of Botox intramuscularly, Adverse Reactions of Botox subdermally
- Drug
- Lead sponsor
- li nguyen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Westminster, California
- Conditions
- Atrial Fibrillation, Coronary Artery Disease
- Interventions
- Regadenoson MRI, Gadobenate dimeglumine
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Interventions
- 18-NaF PET, DCE-MRI, 18-FDG PET/CT
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Coronary Artery Disease
- Interventions
- Coronary MR Angiography (CMRA)
- Other
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Brain Tumor
- Interventions
- Multihance, Arm 2 - Magnevist
- Drug
- Lead sponsor
- Bracco Diagnostics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Uterine Bleeding, Uterine Fibroids, Adenomyosis
- Interventions
- Evaluation of MRI, US for pelvic and uterine conditions, Patient preference between MRI and Ultrasound
- Procedure
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Healthy
- Interventions
- Gadopentetate dimeglumine (Magnevist, BAY86-4882), Moxifloxacin (BAY12-8039), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Central Nervous System Neoplasms
- Interventions
- Not listed
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Interventions
- 3-Tesla magnetic resonance imaging, CEST-MRI, DW-MRI, DCE-MRI, DSC-MRI, IV administration of gadolinium-containing contrast agent
- Device · Drug
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Hepatocellular Carcinoma
- Interventions
- gadobenate dimeglumine (MultiHance)
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland